Prevalence of naturally occurring protease inhibitor resistance-associated variants in hemodialysis and renal transplant patients with hepatitis C virus infection
Carregando...
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2017
Editora
LIPPINCOTT WILLIAMS & WILKINS
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autores
TAVARES, Rita C. F.
FELDNER, Ana C. C. A.
UEHARA, Silvia N. O.
EMORI, Christini T.
CARVALHO-FILHO, Roberto J.
SILVA, Ivonete S. S.
SANTANA, Rubia A. F.
CASTRO, Vanessa F. D. de
CASTOLI, Gregorio T. F.
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, v.29, n.7, p.754-758, 2017
Resumo
Background NS3 protease inhibitors (PIs) were the first direct antiviral agents used for the treatment of hepatitis C virus. The combination of second-wave PIs with other direct antiviral agents enabled the use of interferon-free regimens for chronic kidney disease patients on dialysis and renal transplant (RTx) recipients, populations in which the use of interferon and ribavirin is limited. However, the occurrence of PI resistance-associated variants (RAVs), both baseline and induced by therapy, has resulted in the failure of many treatment strategies. Methods The aim of this study was to estimate the prevalence of PI RAVs and of the Q80K polymorphism in chronic kidney disease patients on hemodialysis and RTx recipients. Direct sequencing of the NS3 protease was performed in 67 patients (32 hemodialysis and 35 RTx). Results RAVs to PIs were detected in 18% of the patients: V55A (9%), V36L (1.5%), T54S (1.5%), S122N (1.5%), I170L (1.5%), and M175L (1.5%). Only 1.5% of the patients carried the Q80K polymorphism. The frequency of these mutations was more than two times higher in patients infected with GT1a (25%) than GT1b (9.7%) (P= 0.1). The mutations were detected in 20% of treatment-naive patients and in 15.6% of peginterferon/ribavirin-experienced patients (P = 0.64). Furthermore, no mutation that would confer high resistance to PIs was detected. Conclusion The Q80K polymorphism was rare in the population studied. The occurrence of RAVs was common, with predominance in GT1a. However, the variants observed were those associated with a low level of resistance to PIs, facilitating the use of these drugs in this special group of patients.
Palavras-chave
chronic kidney disease, hepatitis C virus, kidney transplantation, protease inhibitor, resistance
Referências
- Ahmed A, 2015, VIRUSES-BASEL, V7, P6716, DOI 10.3390/v7122968
- Arenas MD, 2001, NEFROLOGIA, V21, P581
- Asselah T, 2016, LIVER INT, V36, P47, DOI 10.1111/liv.13027
- Bartels DJ, 2008, J INFECT DIS, V198, P800, DOI 10.1086/591141
- Berger KL, 2014, ANTIMICROB AGENTS CH, V58, P698, DOI 10.1128/AAC.01976-13
- Bhamidimarri KR, 2016, J HEPATOL, V65, P7, DOI 10.1016/j.jhep.2016.04.003
- Buti M, 2015, J HEPATOL, V63, P1511, DOI 10.1016/j.jhep.2015.08.010
- Coppola N, 2016, J MED VIROL, V88, P1659, DOI 10.1002/jmv.24527
- [Anonymous], 2014, LANCET, V384, P1756
- de Carvalho IMVG, 2014, J MED VIROL, V86, P1714, DOI 10.1002/jmv.24015
- Di Maio VC, 2016, J ANTIMICROB CHEMOTH, V71, P739, DOI 10.1093/jac/dkv403
- Ewing B, 1998, GENOME RES, V8, P186
- Ewing B, 1998, GENOME RES, V8, P175
- Fabrizi F, 2007, J VIRAL HEPATITIS, V14, P697, DOI 10.1111/1365-2893.2007.00868.x
- Fabrizi F, 2014, J VIRAL HEPATITIS, V21, P681, DOI 10.1111/jvh.12276
- Fabrizi F, 2014, J VIRAL HEPATITIS, V21, P314, DOI 10.1111/jvh.12148
- Gilead, 2013, SOF TREATM CHRON HEP
- Gower E, 2014, J HEPATOL, V61, pS45, DOI 10.1016/j.jhep.2014.07.027
- Halfon P, 2011, J HEPATOL, V55, P192, DOI 10.1016/j.jhep.2011.01.011
- Hauser AB, 2008, PERITON DIALYSIS INT, V28, pS183
- HCV Phenotype Working Group HCV Drug Development Advisory Group, 2012, ANN FORUM COLLAB HIV, V14, P1
- Kidney Disease, 2008, KIDNEY INT S, V109, pS1
- Khedmat Hossein, 2014, Saudi J Kidney Dis Transpl, V25, P1
- Kieffer TL, 2014, CURR OPIN VIROL, V8, P16, DOI 10.1016/j.coviro.2014.04.008
- Kuntzen T, 2008, HEPATOLOGY, V48, P1769, DOI 10.1002/hep.22549
- Lisboa-Neto G, 2015, ANTIVIR THER, V20, P281, DOI 10.3851/IMP2873
- Lontok E, 2015, HEPATOLOGY, V62, P1623, DOI 10.1002/hep.27934
- Marinaki S, 2015, WORLD J HEPATOL, V27, P548
- McCloskey RM, 2015, J INFECT DIS, V211, P1288, DOI 10.1093/infdis/jiu613
- Messina JP, 2015, HEPATOLOGY, V61, P77, DOI 10.1002/hep.27259
- Morales JM, 2015, NAT REV NEPHROL, V11, P172, DOI 10.1038/nrneph.2015.5
- Paolucci S, 2012, VIROL J, V24, P245
- Paolucci S, 2015, J CLIN VIROL, V72, P114, DOI 10.1016/j.jcv.2015.08.015
- Pawlotsky JM, 2016, GASTROENTEROLOGY, V151, P70, DOI 10.1053/j.gastro.2016.04.003
- Peres-da-Silva A, 2010, ARCH VIROL, V155, P807, DOI 10.1007/s00705-010-0642-z
- Peres-da-Silva A., 2012, MEM I O CRUZ, V107, P254
- Perez RM, 2003, J MED VIROL, V69, P489, DOI 10.1002/jmv.10336
- Poveda E, 2014, ANTIVIR RES, V108, P181, DOI 10.1016/j.antiviral.2014.05.015
- Sarrazin C, 2016, J HEPATOL, V64, P486, DOI 10.1016/j.jhep.2015.09.011
- Sarrazin C, 2015, ANTIVIR RES, V116, P10, DOI 10.1016/j.antiviral.2015.01.003
- Sawinski D, 2016, AM J TRANSPLANT, V16, P1588, DOI 10.1111/ajt.13620
- Simmonds P, 2005, HEPATOLOGY, V42, P962, DOI 10.1002/hep.20819
- SIMMONDS P, 1994, HEPATOLOGY, V19, P1321, DOI 10.1016/0270-9139(94)90887-7
- Singh T, 2016, LIVER INT, V36, P802, DOI 10.1111/liv.13078
- Smith DB, 2014, HEPATOLOGY, V59, P318, DOI 10.1002/hep.26744
- Su YY, 2013, HEMODIAL INT, V17, P532, DOI 10.1111/j.1542-4758.2012.00761.x
- Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121
- Welsch Christoph, 2014, Drug Discov Today Technol, V11, P19, DOI 10.1016/j.ddtec.2013.12.003
- Wiegand J, 2014, ALIMENT PHARM THER, V39, P1342, DOI [10.1111/apt.12748, 10.1111/apt.12738]
- Wu S, 2013, WORLD J GASTROENTERO, V19, P8940, DOI 10.3748/wjg.v19.i47.8940
- Wyles DL, 2013, J INFECT DIS, V207, pS33, DOI 10.1093/infdis/jis761